Mifepristone

Contraindicated

Mifepristone Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure Details Mifepristone Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Mifepristone Simvastatin Flolipid Explained Increased simvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Mifepristone Abemaciclib Verzenio Explained Increased CYP3A4 substrate with NTI exposure Details Mifepristone Acalabrutinib Calquence Increased CYP3A4 substrate with NTI exposure Details Mifepristone Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure Details Mifepristone Beclomethasone Nasal Spray Beconase Increased beclomethasone exposure, an increased risk of beclomethasone-related adverse reactions, an increased risk of autoimmune... Details Mifepristone Beclomethasone Oral Inhalation Beclovent® Increased beclomethasone exposure, an increased risk of beclomethasone-related adverse reactions, an increased risk of autoimmune... Details Mifepristone Bosutinib Bosulif Increased CYP3A4 substrate with NTI exposure Details Mifepristone Brigatinib Alunbrig Increased CYP3A4 substrate with NTI exposure Details Mifepristone Budesonide Entocort Increased CYP3A4 substrate exposure and an increased risk of autoimmune disorders and acute adrenal insufficiency, that may lead t... Details Mifepristone Budesonide Nasal Spray Rhinocort Increased CYP3A4 substrate exposure and an increased risk of autoimmune disorders and acute adrenal insufficiency, that may lead t... Details Mifepristone Budesonide Oral Inhalation Pulmicort Increased CYP3A4 substrate exposure and an increased risk of autoimmune disorders and acute adrenal insufficiency, that may lead t... Details Mifepristone Ciclesonide Nasal Spray Omnaris An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Ciclesonide Oral Inhalation Alvesco An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure Details Mifepristone Clindamycin Topical C/T/S® Increased CYP3A4 substrate with NTI exposure Details Mifepristone Clindamycin Vaginal Cleocin Increased CYP3A4 substrate with NTI exposure Details Mifepristone Clobetasol Byqlovi An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Clobetasol Topical Clobex® An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Cobimetinib Cotellic Increased CYP3A4 substrate with NTI exposure Details Mifepristone Cyclosporine Injection Atopica Increased cycloSPORINE exposure and an increased miFEPRIStone exposure Details Mifepristone Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure and an increased miFEPRIStone exposure Details Mifepristone Dasatinib Phyrago Increased dasatinib exposure and an increased risk of QT interval prolongation Details Mifepristone Deflazacort Emflaza Increased CYP3A4 substrate exposure and an increased risk of autoimmune disorders and acute adrenal insufficiency, that may lead t... Details Mifepristone Desonide Desowen An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Desonide Topical Desonate® An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Desoximetasone Topicort An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Desoximetasone Topical Topicort An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Deuruxolitinib Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Mifepristone Dexamethasone Injection Decadron Reduced miFEPRIStone exposure, reduced efficacy of miFEPRIStone, increased dexAMETHasone exposure, an increased risk of autoimmune... Details Mifepristone Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced miFEPRIStone exposure, reduced efficacy of miFEPRIStone, increased dexAMETHasone exposure, an increased risk of autoimmune... Details Mifepristone Diflorasone Topical Apexicon An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Difluprednate Ophthalmic Durezol An increased risk of autoimmune disorders and an increased risk of acute adrenal insufficiency, that may lead to exacerbation or d... Details Mifepristone Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and risk of adverse events Details Mifepristone Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and risk of adverse events Details Mifepristone Docetaxel Beizray Increased CYP3A4 substrate with NTI exposure Details Mifepristone Docetaxel Injection Beizray Increased CYP3A4 substrate with NTI exposure Details Mifepristone Dofetilide Tikosyn Increased dofetilide exposure and an increased risk of QT interval prolongation Details Mifepristone Entrectinib Rozlytrek Increased entrectinib exposure, increased miFEPRIStone exposure and an increased frequency or severity of adverse reactions includ... Details